ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc (ATNM)

1.86
-0.10
(-5.10%)
마감 16 9월 5:00AM
1.86
0.00
(0.00%)
시간외 거래: 5:50AM

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
1.86
매수가
-
매도가
-
거래량
289,939
1.82 일간 변동폭 2.01
1.33 52주 범위 15.12
market_cap
전일 종가
1.96
개장가
1.96
최근 거래 시간
16595
@
1.86
마지막 거래 시간
재정 규모
US$ 544,471
VWAP
1.8779
평균 볼륨(3m)
582,659
발행 주식
31,154,376
배당수익률
-
주가수익률
-1.19
주당순이익(EPS)
-1.57
매출
81k
순이익
-48.82M

Actinium Pharmaceuticals Inc 정보

Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and re... Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ('r/r AML'), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ('NCI') under the Cooperative Research and Development Agreement ('CRADA') for development of Actimab-A in AML and other myeloid malignancies. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Actinium Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 아메리카 증권거래소 with ticker ATNM. The last closing price for Actinium Pharmaceuticals was US$1.96. Over the last year, Actinium Pharmaceuticals shares have traded in a share price range of US$ 1.33 to US$ 15.12.

Actinium Pharmaceuticals currently has 31,154,376 shares in issue. The market capitalisation of Actinium Pharmaceuticals is US$61.06 million. Actinium Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.19.

ATNM 최신 뉴스

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. PR Newswire NEW YORK, Aug. 5, 2024 FDA determined that the Phase 3 SIERRA trial is not adequate...

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications PR...

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University PR...

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US PR Newswire NEW YORK, July 25, 2024 Presentation to highlight positive outcomes of Iomab-B led bone...

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid...

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial PR Newswire NEW YORK, June...

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting PR Newswire NEW...

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.09-4.615384615381.952.281.684836671.95233551CS
4-5.71-75.4293262887.578.641.338424773.18164222CS
12-4.71-71.68949771696.5710.241.335826594.97772373CS
26-5.14-73.4285714286710.241.333890545.15243839CS
52-4.21-69.35749588146.0715.121.333562217.25794521CS
1561.625691.4893617020.23515.120.150617818401.54261008CS
2600002.01000CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AIRIAir Industries Group
US$ 7.39
(18.05%)
410.59k
QULLETRACS 2x Leveraged MSCI US Quality Factor TR ETN
US$ 54.43
(14.84%)
8
HNRAHNR Acquisition Corp
US$ 1.1693
(14.64%)
172.32k
TOVXTheriva Biologics Inc
US$ 4.09
(13.61%)
216.38k
GROYGold Royalty Corp
US$ 1.38
(11.29%)
4.04M
BURUNuburu Inc
US$ 0.4375
(-27.22%)
1.81M
MYNDMynd ai Inc
US$ 1.12
(-12.50%)
79.41k
DDCDDC Enterprise Limited
US$ 0.3001
(-11.74%)
443.21k
AAMCAltisource Asset Management Corporation
US$ 1.3101
(-9.65%)
40.5k
BEEPMobile Infrastructure Corporation
US$ 3.12
(-9.04%)
67.33k
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 33.43
(5.09%)
71.17M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 23.29
(-5.09%)
50.48M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 7.18
(-1.51%)
42.33M
SPYSPDR S&P 500
US$ 562.01
(0.52%)
36.16M
IWMiShares Russell 2000
US$ 216.83
(2.47%)
35.1M

ATNM Discussion

게시물 보기
grubstake grubstake 49 분 전
Thanks Timber (I think you dropped CRMD here too, my brother has some, that one’s moving of late.)Yes once ICU gets approval for ADULT aki… much bigger population. I remember them alluding to potential use for organ transplant treatment in future, and many other paths. Just looked up Ihub ICU board: https://investorshub.advfn.com/SeaStar-Medical-Holding-Corp-ICU-42335
Now back to our ATNM waiting for some good news… that brings us back to $6 then $10… :c
👍️0
timberwolf7 timberwolf7 2 일 전
On ICU... only 4 or so Mil shares, thats nice to see (course they did a r/split to get there)

Bigger issue may be the SMALL population of potential patients in terms of who THEY see
as their potential 'market'..

Interesting 'development', something I am familiar with in terms of it basically being a
blood 'conditioner'. Got to look into how well it really works from the aspect of, if someone
gets this 'condition', will the facility see their development as something they HAVE to try.

On NSPR, I don't own any yet. Still watching the momentum which is weighing negative,
but the share price is resisting breaking down, holding $2.7. Was hoping it would drop to $2.50
or less...But will be getting some before their next earnings call just in case they say something along
the lines of revenues/sales in the overseas markets continues to move higher..
👍️ 1
grubstake grubstake 3 일 전
I learned of nspr from you here, it was a buck and I missed it as it went through $2, I hold some now but at par. Shoulda listened at $1! ICU is unique though (not ICUI) with apparent blue skies on many fronts, time factor and burn rate holding them back. https://journey.ct.events/view/7f792b7c-2391-4da5-9718-55622babdcae thanks for reply…
not for the faint of heart!
👍️ 1
timberwolf7 timberwolf7 3 일 전
Oops, wrong company.. Meant AWE platform for attacking solid tumors...

If you are looking at something to get into, check out NSPR.. They have just submitted an application for approval for a
stent design that IS a lot better than the current technology being used. They are anticipating a decision in the 1st half of 2025.
I have traded the shares a couple of times in the past, have a 'very conservative' initial target price of $5. Which from the current
price of around $2.75, would be around a 80% POTENTIAL return IF the fda approves their medical DEVICE (not a drug). Which
is already approved overseas and is being sold/used. (but no secret, you want to generate serious revenues, you need to be approved
to sell into the US market).
Disclaimer: I don't own any at the moment, just watching to see if the share price will keep slipping off its recent highs from the news
that they submitted their application.
NOTE; will check into ICU, but from an initial quick look at what they are doing, I prefer to find companies that are doing something much better
than whats already on the market, or something NEW... AKA, ATNMs conditioner effort and still can't believe what happened to them.

https://www.actiniumpharma.com/awe-technology

Actinium's Antibody Warhead Enabling (AWE) Technology Platform
Actinium's AWE technology platform is used to produce ARCs or Antibody Radiation Conjugates, a highly potent and selective form of targeted radiotherapy. ARCs enable the precision targeting of the proven therapeutic power of radiation to tumors and its synergistic potential with other therapeutic modalities that cannot be matched by traditional external beam radiation, cytotoxic chemotherapy or biologic therapies. AWE enabled ARCs exploit the use of highly selective targeted biological agents such as monoclonal antibodies that can seek out and bind cancer antigens found on the tumor cell surface to deliver potent radioisotopes that are capable of producing double strand DNA breaks for which there is no known resistance or repair mechanisms.
👍️ 2
grubstake grubstake 3 일 전
Timber please, what is WAR programs?…
I tried to get a comment from ATNM investor relations on situation but no response.
also, have you looked into ICU stock? thanks
👍️0
timberwolf7 timberwolf7 4 주 전
On a possible buyout. Yep, this screw job by the fda could be part of something
to corner ATNM management into doing something they weren't prepared to do.

The other question I hadn't really spent much time on yet is, just how good is their
WAR programs? How good/effective is the technology.

.
👍️0
Stantheplan Stantheplan 1 월 전
With the recent price drop the majority shareholders in ATNM may be softened up enough to accept a much lower buyout price for the company but the question is will Seth be willing to sell. If he does it will be before Thanksgiving of this year imo.
👍️0
timberwolf7 timberwolf7 1 월 전
Worst part is, their development appears to actually HELP people

So why in the hell would the fda say, redo the trial vs
do a PH 4 follow up trial following approval.

Unfricking real..
👍️ 1
timberwolf7 timberwolf7 1 월 전
Yeah, I sold out some years ago as well, held off taking a new position until recently.

Got a 1000 shares at $7.55, have $900 in profits off the covered calls. So going to keep doing that
while this gets figured out. Only concern is whats going to happen to the value of the calls as this
quiets down.. Might be tough to get a lot for them.

Yep, have seen enough out of the fda to again, realize its integrity has been compromised.. And that
IS NOT a good thing..

But sadly, its just a reflection of the overall breakdown in morals, ethics, integrity, honesty in this world now.
Replaced by the desire for GREED and POWER no matter what gets sacrificed to get it.
👍️0
Pharmboy46 Pharmboy46 1 월 전
Thank you for your reply which confirms my feelings regarding FDA’s lack of integrity surrounding the approval process. I’m happy that I sold about half of my position a couple of years ago (at around 12). I guess we wait for an unsatisfying buyout?
👍️0
timberwolf7 timberwolf7 1 월 전
Yep, thats my understanding as well. They concurred in the trial, which means they
had agreed on the 'acceptance' criteria.

But at least this explains WHY its taken them so long to announce filing for approval.

And been a long time observer/concluder that the FDA doesn't have the publics best
interest as their primary goal. Figured it out some years ago that big pharma runs the
fda, guides its 'decisions'.

Even to the point where I have suspected that new ideas trying that are 'targets' by
a big pharma who would like to own the idea, may find it harder to get to their end point.
To the point they become illiquid and forced to 'negotiate' just so that the developers can
get something for their efforts.

Or even worse, in this case, since this does appear to HELP people going thru treatment,
that despite this conclusion, the fda doesn't give a damn that it does. And once again, instead
of saying, we will approve but you have to do a PH 4 followup to conclude just how well it works.
We are going to flat out DENY the ones that could benefit from this from using it to help extend/save
their lives. Nope, we are going to endanger lives instead by DENYING them a potential treatment
that has shown it can help them. That to me is the really sick part of this mess.

Yep, sure appears to be a royal screw job. Not just for ATNM, but really for those that it could HELP.
👍️ 1
Pharmboy46 Pharmboy46 1 월 전
I believe it was Astra Zenica buying Force Pharmaceuticals?
👍️0
grubstake grubstake 1 월 전
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
Can they get approval outside the US?
👍️0
grubstake grubstake 1 월 전
Perhaps a new partner is on the bid…?
With deep pockets…
Did the drug makers pressure fda to force this?
👍️0
north40000 north40000 1 월 전
Did some company like ABBV or ABT or GSK buy that other Actinium using company?
👍️0
Pharmboy46 Pharmboy46 1 월 전
There are other companies that use the radio therapeutic actinium investigationally. FDA has approved its use in clinical trials to treat prostate, breast and other solid tissue cancers, but, I couldn’t find any information on any company that holds marketing approval.
👍️0
north40000 north40000 1 월 전
Didn’t FDA just approve another company’s drug that also contained actinium?
👍️0
Pharmboy46 Pharmboy46 1 월 전
I think they are mostly big pharma- centered. The deck is truly stacked against the smaller players. It’s a shame because most of the true innovation comes from the small guys!
👍️0
Zadie420 Zadie420 1 월 전
FDA is a criminal agency. How could exert a pressure on patients not to cross over when it comes to life and death. FDA needs to use ECA and other documented data to compare and evaluate the results.
👍️0
Pharmboy46 Pharmboy46 1 월 전
The message from the company is that they have to run a whole new trial (apparently without a cross over option)
👍️0
Zadie420 Zadie420 1 월 전
Now what kind of test they want to run? Is it full trial size or what?
👍️0
Pharmboy46 Pharmboy46 1 월 전
Wow. The FDA really screwed us on this one. One must question if the FDA really has the public’s interest in mind when making these decisions. If I’m understanding it correctly, FDA approved the SIERRA study, even went so far as to say that it would be enough to garner approval, then decided that it wasn’t enough to file a BLA?
👍️0
timberwolf7 timberwolf7 1 월 전
fda just screwed ATNM over by telling them the trials acceptance criteria (which the FDA 'accepted' when the trial was
put together) needs to be changed.

https://ir.actiniumpharma.com/press-releases/detail/486
👍️0
timberwolf7 timberwolf7 2 월 전
Would like to see them get their NDA submitted already.

Be nice to see them advancing their first product to market to start generating

some revenues.

For everything else they are 'spending' cash on is years from generating revenue unless

its good enough for them to be bought out or gain a partnership.
👍️0
grubstake grubstake 2 월 전
Today’s news was interesting in that atnm Will start on path developing new method to treat sickle cell cases. This will have the attention of.Vertex as an alternative to chemo. VRTX is working with CRSP on their first approved treatment using CRSPR TECHNOLOGY for sickle disease . It would be quite nice for.ATNM to rub shoulders withVRTX and CRSP as they have very deep pockets! Might pull in those calls LOL
👍️0
timberwolf7 timberwolf7 2 월 전
LOL...

Nope, been a while since I was serious about holding shares for the NDA submission.

But noticed the calls have some 'value' to them, and also that accumulation occurred in

APRIL, MAY and its happening again now. (have a sentiment indicator I monitor on the

charting software I use)..

Should actually send a message to their IR and ask them to update folks on their

NDA submission status. Like what in the heck is taking so long (smile)
👍️0
oldstocks oldstocks 2 월 전
Not much posting here, so you are the one buying all the shares to take it to $10?

Thank you

No really it is moving up nicely
👍️0
timberwolf7 timberwolf7 2 월 전
Started my accumulation of shares this morn.

But also selling covered calls on the shares while I wait.

Got shares at $7.55 and sold the Sept $10 Strike price for .55 cents/..

good way to get some gains, hopefully hold onto the shares in the process.

Good luck.
👍️0
dinogreeves dinogreeves 3 월 전
Oddly 5400 volume after hours.
👍️0
dinogreeves dinogreeves 3 월 전
Something is up with this one.
👍️0
dinogreeves dinogreeves 3 월 전
The time to be in is right before close on Friday. News could be over the weekend and Monday morning nice gap and run.
👍️0
dinogreeves dinogreeves 3 월 전
ATNM with BLA news, should realistically hit 30 dollars minimum in multiple days.
🤥 1
dinogreeves dinogreeves 3 월 전
Way too much manipulation on level 2, been watching the trades for the past 2 weeks, that is why I got in yesterday.
👍️0
dinogreeves dinogreeves 3 월 전
Who knows BLA is suppose to be this month, not holding my breath though. Either this month or sometime in after July 4th. What I am seeing is people getting in for news everyday and when news doesn't come they sell the next day.
🕳️ 1 🪦 1 ☠️ 1 ⚰️ 1
timberwolf7 timberwolf7 3 월 전
I don't own any at the moment. Been a while actually since I have held any position for that matter

That said, with the announcement of the filing of the NDA anticipated sometime between the end of
June and December??

Been thinking of 'playing' the announcement. But at the moment, ATNM is in a confirmed
downtrend. So going to be patient to see what this gets down to first..

Do like the Nov %5s for $3.20/ 2x as many vs the shares and only a $ in 'premium'.

But again, see how low this goes first..

Good luck
👍️0
dinogreeves dinogreeves 3 월 전
Bought 90 calls all the way out to November in the money, also bought 1500 shares at the end of day.
🤥 1
timberwolf7 timberwolf7 3 월 전
popping on the news of a PH 1 trial.. so they buying to take what

the news 'gives' this morn or are they buying to hold the shares for

the next 2 - 2+ years till the PH 2 is over and reads out

Just read their MAY 2024 presentation and see they are now

targeting the 2nd HALF of 2024 for an NDA on IO-B.. taking a

long time to get this NDA submitted, and then take on another 9

months for a decision. Mercy...

IE, don't expect the share price to do much until they announce the NDA submission now,

and then it will be up to the PH 2s on the ARC developments to give us insights into what its

potential really is..

Good luck
👍️0
north40000 north40000 3 월 전
Maybe soon. ATNM trading at $8.40 this morning, pre-market opening, +7.42%.
👍️0
Pharmboy46 Pharmboy46 5 월 전
Good luck. Something’s gotta give soon! I’d love to see that 25 dollar mark before the end of the year.
👍️0
timberwolf7 timberwolf7 5 월 전
Back in with the first buy in a long time... Still have a target price of $25.. Ticked that CRMD has taken so long to get going cause it made me miss one heck of a buying opp on ATNM sub $5...

Now to start selling covered calls and see if I can keep the shares..


Good luck..
👍️0
Monroe1 Monroe1 6 월 전
The troll idiot rides again making up lies when his ass gets burned.

LMAO, what a piece of work.
👍️0
fung_derf fung_derf 6 월 전
LOL!! Is this your "timing" post?? Yes, you only made it 8 years ago....great timing....of course the stock was around $62 then

Monroe1

Re: None

Tuesday, September 27, 2016 10:17:02 AM

Post#
1092
of 2790
So what is the ETA for lomab coming out of phase3 and approval?
Mid 2017 or earlier perhaps??
👍️0
north40000 north40000 6 월 전
Suppose that PT is raised in light of AZN buying Fusion at ~ 100% premium today? Much needed Actinium involved there also
👍️0
oldstocks oldstocks 6 월 전
Maxim Group Maintains Buy on Actinium
Pharma, Raises Price Target to $30
3/19/2024 12:59pm
12:59 PM EDT, March 19, 2024 (Benzinga Newswire)
Maxim Group analyst Jason McCarthy maintains
Actinium Pharma (AMEX:ATNM) with a Buy and raises the price target from $20 to $30.
Write to Benzinga at editorial@benzinga.com
👍️0
Pharmboy46 Pharmboy46 6 월 전
I continue to believe that potential suitors are waiting for ATNM to, at the very least, submit their application to the FDA. Possibly the company even had some offers but would be in a better position to negotiate after approval?
👍️0
oldstocks oldstocks 6 월 전
Watching Actinium Pharmaceuticals; HC
Wainwright: First Take Says 'Appetite Remains High For Radiopharmaceuticals;
We See Actinium As Ripe For Takeout And Believes It Is Receiving M&A Interest'
3/19/2024 11:24am
👍️0
oldstocks oldstocks 6 월 전
HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target
3/19/2024 11:19am
11:19 AM EDT, March 19, 2024 (Benzinga Newswire)
HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.
Write to Benzinga at editorial@benzinga.com
👍️0
Pharmboy46 Pharmboy46 6 월 전
Good news but we can sure use that FDA submission.
👍️0
oldstocks oldstocks 6 월 전
Actinium Pharmaceuticals Disclosed The Launch Of Strategic Initiative Focused On The Manufacture Of The Highly Sought After Medical Isotope Actinium-225 (Ac-225)
3/14/2024 6:11am
👍️ 1
oldstocks oldstocks 6 월 전
News 3-11-2024
https://www.otcmarkets.com/stock/ATNM/news/story?e&id=2791660
👍️0

최근 히스토리

Delayed Upgrade Clock